Literature DB >> 24618543

Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function.

Evan L Brittain1, Meredith E Pugh, Lisa A Wheeler, Ivan M Robbins, James E Loyd, John H Newman, Emma K Larkin, Eric D Austin, Anna R Hemnes.   

Abstract

Abstract Although individuals with familial pulmonary arterial hypertension (FPAH) have more severe hemodynamics, compared to individuals with idiopathic PAH (IPAH), it is unclear whether this translates into a survival difference. The influence of right ventricular (RV) function on survival in these groups is also unknown. We reviewed hemodynamic data and health information from a prospective institutional database of 57 FPAH and 66 IPAH patients registered with the Vanderbilt Pulmonary Hypertension Research Cohort. We compared hemodynamics at the time of diagnosis between the two groups and calculated pulmonary arteriolar capacitance (PC) and RV stroke work index (RVSWI). Using survival analysis, we compared freedom from a 5-year composite of death or lung transplantation in FPAH and IPAH patients. The composite outcome of death or transplant at 5 years from diagnosis was significantly increased in FPAH (log rank [Formula: see text]). PC and RVSWI were significantly decreased in FPAH, compared to IPAH ([Formula: see text] for both). In univariate analysis, PC (odds ratio [OR]: 0.17 [95% confidence interval (95% CI): 0.03-0.83]) and RVSWI (OR: 0.86 [95% CI: 0.77-0.95]) were predictors of mortality, as were cardiac index (OR: 0.17 [95% CI: 0.06-0.51]) and PVR (OR: 1.1 [95% CI: 1.01-1.12]). Among FPAH patients, RVSWI was lower in those who died or received a transplant than in survivors ([Formula: see text]), while PC was not ([Formula: see text]). We found significantly worse event-free survival and significantly lower PC and RVSWI in FPAH than in IPAH. In FPAH patients who died or underwent transplantation, RVSWI was lower than that in survivors, suggesting disproportionate RV dysfunction.

Entities:  

Year:  2013        PMID: 24618543      PMCID: PMC4070798          DOI: 10.1086/674326

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  32 in total

1.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

2.  Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Cherylanne Glassner; Mardi Gomberg-Maitland
Journal:  Chest       Date:  2011-09-01       Impact factor: 9.410

3.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension.

Authors:  T C Yeo; K S Dujardin; C Tei; D W Mahoney; M D McGoon; J B Seward
Journal:  Am J Cardiol       Date:  1998-05-01       Impact factor: 2.778

4.  Right ventricular function predicts transplant-free survival in idiopathic dilated cardiomyopathy.

Authors:  Luigi La Vecchia; Leonardo Varotto; Luisa Zanolla; Gian Luca Spadaro; Alessandro Fontanelli
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2006-09       Impact factor: 2.160

5.  Tricuspid annular displacement predicts survival in pulmonary hypertension.

Authors:  Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2006-08-03       Impact factor: 21.405

6.  Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

Authors:  Marc Humbert; Olivier Sitbon; Ari Chaouat; Michèle Bertocchi; Gilbert Habib; Virginie Gressin; Azzedine Yaïci; Emmanuel Weitzenblum; Jean-François Cordier; François Chabot; Claire Dromer; Christophe Pison; Martine Reynaud-Gaubert; Alain Haloun; Marcel Laurent; Eric Hachulla; Vincent Cottin; Bruno Degano; Xavier Jaïs; David Montani; Rogério Souza; Gérald Simonneau
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

7.  Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.

Authors:  Roela Sadushi-Koliçi; Nika Skoro-Sajer; Daniel Zimmer; Diana Bonderman; Michael Schemper; Walter Klepetko; Jutta Glatz; Johannes Jakowitsch; Irene M Lang
Journal:  J Heart Lung Transplant       Date:  2012-04-04       Impact factor: 10.247

Review 8.  Genetics and mediators in pulmonary arterial hypertension.

Authors:  Eric D Austin; James E Loyd
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

9.  Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.

Authors:  Benjamin Sztrymf; Florence Coulet; Barbara Girerd; Azzedine Yaici; Xavier Jais; Olivier Sitbon; David Montani; Rogério Souza; Gerald Simonneau; Florent Soubrier; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2008-03-20       Impact factor: 21.405

10.  Survival in pulmonary arterial hypertension: A brief review of registry data.

Authors:  Sunil Pauwaa; Roberto F Machado; Ankit A Desai
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

View more
  16 in total

1.  Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

2.  Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension.

Authors:  Evan L Brittain; Meredith E Pugh; Lisa A Wheeler; Ivan M Robbins; James E Loyd; John H Newman; Eric D Austin; Anna R Hemnes
Journal:  JACC Heart Fail       Date:  2013-08       Impact factor: 12.035

3.  BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes.

Authors:  Anna R Hemnes; Joshua P Fessel; Xinping Chen; Shijun Zhu; Niki L Fortune; Christopher Jetter; Michael Freeman; John H Newman; James D West; Megha H Talati
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-12-18       Impact factor: 5.464

4.  Pulmonary arterial capacitance predicts outcomes in patients with pulmonary hypertension independent of race/ethnicity, sex, and etiology.

Authors:  Jacob J Mayfield; Alexander Papolos; Elena Vasti; Teresa De Marco; Geoffrey H Tison
Journal:  Respir Med       Date:  2020-02-04       Impact factor: 3.415

Review 5.  Microvessel mechanobiology in pulmonary arterial hypertension: cause and effect.

Authors:  Nathaniel C Bloodworth; James D West; W David Merryman
Journal:  Hypertension       Date:  2014-12-22       Impact factor: 10.190

6.  Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension.

Authors:  Levi Benson; Evan L Brittain; Meredith E Pugh; Eric D Austin; Kelly Fox; Lisa Wheeler; Ivan M Robbins; Anna R Hemnes
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

7.  Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.

Authors:  Megha H Talati; Evan L Brittain; Joshua P Fessel; Niki Penner; James Atkinson; Mitch Funke; Carrie Grueter; W Gray Jerome; Michael Freeman; John H Newman; James West; Anna R Hemnes
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

8.  Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Evan L Brittain; Aaron W Trammell; Joshua P Fessel; Eric D Austin; Niki Penner; Karen B Maynard; Linda Gleaves; Megha Talati; Tarek Absi; Thomas Disalvo; James West
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

Review 9.  Using Omics to Understand and Treat Pulmonary Vascular Disease.

Authors:  Anna R Hemnes
Journal:  Front Med (Lausanne)       Date:  2018-05-24

10.  Unbiased Phenome-Wide Association Studies of Red Cell Distribution Width Identifies Key Associations with Pulmonary Hypertension.

Authors:  Timothy E Thayer; Shi Huang; Rebecca T Levinson; Eric Farber-Eger; Tufik R Assad; Jessica H Huston; Jonathan D Mosley; Quinn S Wells; Evan L Brittain
Journal:  Ann Am Thorac Soc       Date:  2019-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.